Background {#Sec1}
==========

Age-related macular degeneration (AMD) is the most common cause of vision loss in senior citizens \[[@CR1]--[@CR3]\]. One of the first signs of AMD is the appearance of yellowish drusen between the retinal pigment epithelium (RPE) and Bruch's membrane. Drusen comprise extracellular deposits of proteins and lipids and predispose individuals to develop the degenerative late-stage form of the disease \[[@CR4]\]. Late-stage AMD manifests as geographic atrophy (GA) or neovascular (NV) AMD although both late-stage forms can be present in the same or in different eyes of a single individual (mixed GA + NV). GA affects up to 50% of people with late-stage AMD and is defined as a discrete region of RPE atrophy. NV AMD describes the abnormal growth of leaky blood vessels from the choroid or from within the retina resulting in detachment of the RPE, strong immune cell activation, photoreceptor cell death, and eventually widespread RPE damage. Although vision loss is more rapid in NV AMD, visual acuity can be preserved by anti-angiogenic treatment \[[@CR5], [@CR6]\].

Over the past decade, genome-wide association studies (GWAS) have identified a number of single nucleotide variants (SNVs) as well as copy number variations in complement and complement-related genes that are involved in AMD risk \[[@CR7]--[@CR12]\]. Recently, the International AMD Genomics Consortium (IAMDGC) \[[@CR13]\] identified 52 independent genetic variants at 34 loci across the genome to be associated with late-stage AMD, explaining up to 50% of the heritability of this disorder.

The genetic risk of an individual to develop a disease can be expressed as a genetic score. One concept to calculate such a score is to count the number of risk-increasing alleles. To account for differences between the effect sizes of genetic variants (i.e. the relative influence of each variant on disease risk), the score can be calculated as the weighted sum of risk increasing alleles using the relative effect size of a variant as weight \[[@CR14]\]. Such scores effectively summarize the genetic contribution to diseases or traits and allow evaluation of the genetic risk of other diseases and traits and its correlation with AMD risk.

To evaluate shared genetics between AMD and other complex diseases or disease-relevant traits, we computed genetic scores from published genome-wide significant lead variants for 60 diseases and traits \[[@CR15]--[@CR81]\] and examined their association with AMD using data from a large AMD case-control study including more than 33,000 participants.

Methods {#Sec2}
=======

Description of dataset {#Sec3}
----------------------

In total, we included data from 16,144 people with late-stage AMD (NV, GA, or both, GA/NV AMD) and 17,832 control individuals without AMD, all unrelated and of European ancestry \[[@CR13]\]. Inclusion and exclusion criteria as well as detailed information on ophthalmological grading, quality control of genetic data as well as imputation are given in detail elsewhere \[[@CR13]\]. The dataset contained 14,352 men and 19,624 women. Twenty-six studies with different study designs contributed to this dataset, including six population-based studies (2166 cases, 4246 controls).

Diseases and traits under evaluation {#Sec4}
------------------------------------

We searched PubMed ([www.pubmed.gov](http://www.pubmed.gov/)) for GWAS of human diseases and traits which included primarily individuals of European descent and publication dates prior to April 2016 (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). In addition, we queried GWAS Central ([www.gwascentral.org/browser](http://www.gwascentral.org/browser)) using the same criteria. GWAS were excluded when no genome-wide significant variants (*p* \< 5.00 × 10^--8^ or log10 p \< --7.3010) were reported or when relevant data such as effect sizes, effect alleles, or *p* values of association were missing. We also excluded GWAS dealing with diseases and traits mainly attributable to childhood or pregnancy and behavioral/lifestyle traits. In total, we selected 60 human diseases or traits that were eligible for further analysis.

Calculation of genetic (risk) scores {#Sec5}
------------------------------------

For each of the 60 diseases/traits, we extracted independent genetic variants associated with each of the diseases/traits from the relevant publication, provided their individual association reached genome-wide significance (p \< 5.00 × 10^--8^ or log10 p \< --7.3010) (Additional file [1](#MOESM1){ref-type="media"}: Figure S1 and Additional file [2](#MOESM2){ref-type="media"}: Table S1). SNVs were included with an imputation quality \> 0.3, but only those for which we could determine the risk increasing (effect) allele and the associated effect size. Structural variants (e.g. deletions or duplications) were included if they could be imputed reliably (imputation quality \> 0.3) into the IAMDGC dataset. Otherwise, if available, proxy variants with R^2^ \> 0.95 with sufficient imputation quality were chosen. In this analysis, a locus region was defined by a genome-wide significant variant and variants within ± 1 Mbp. For each locus, only the lead variant (i.e. the variant with the smallest *p* value for association) was included to represent the relevant disease-/trait-associated haplotype. In a few cases with multiple independent variants reported within a locus, we included all of these. We excluded diseases/traits with less than three genome-wide significant variants published. To account for differences in effect sizes, we extracted the relevant measure of the effect for each of the identified variant (log odds ratio \[LOR\] for binary outcome, log hazard ratio \[HR\] for survival, or slope for continuous outcome) from published sources for the respective lead variant (Additional file [2](#MOESM2){ref-type="media"}: Table S1).

For each disease/trait, the genetic score was calculated as reported in \[[@CR14]\] with slight modifications. Briefly, the number of risk increasing alleles, each weighted (multiplied) by the respective effect size (LOR, log HR, or linear regression slope), were counted and the total divided by the average weight. Thus, an individual with a genetic score that is one unit larger than the genetic score of another individual has one additional risk-increasing allele with average effect size. An individual with a genetic score of 50 would have 50 "average" risk-increasing alleles. In addition to the 60 genetic scores for the selected diseases/traits, we computed the genetic score for AMD based on 52 identified independent AMD variants \[[@CR13]\].

The diseases/traits included in the study and the respective publications used to extract the variants and effect sizes are listed in Additional file [2](#MOESM2){ref-type="media"}: Table S1. The variants of the traits that were included in the analysis and further information on these variants are listed in Additional file [3](#MOESM3){ref-type="media"}: Table S2.

Correlation between genetic scores and variance explained {#Sec6}
---------------------------------------------------------

We computed the correlation coefficient between selected genetic scores in R \[[@CR82]\]. The results were plotted with the function heatmap2 from the gplots package \[[@CR83]\] using a diverging color palette implemented in the package RColorBrewer \[[@CR84]\]. In addition, we estimated the disease/trait variance explained by each variant used to calculate the individual genetic score. In case the disease/trait is dichotomous (e.g. coronary artery disease or psoriasis \[PSO\]), we extracted the relevant ORs and allele frequencies and calculated the variance explained using a liability threshold model \[[@CR85]\]. In case a disease/trait is continuous (e.g. body mass index, height), we calculated the variance explained directly from the respective linear slopes and standard errors.

Association of the genetic scores with AMD {#Sec7}
------------------------------------------

To understand the role of the genetic background of each of the 60 diseases/traits for AMD, we conducted association analyses for each of the 60 genetic scores with AMD using logistic regression. Each model was adjusted for DNA source (whole genome amplification: yes/no) and principal components to control for potential subpopulations. Additionally, adjustments were done for age and gender \[[@CR13]\].

To account for the multiple association testing of the 60 genetic scores, which were correlated due to shared variants or loci, we controlled the false discovery rate (FDR) to be smaller than 1% \[[@CR86]\].

The strength of association of genetic scores and variants are reported as the log odds ratio (LOR). The OR depicts the AMD risk increase per unit increase in the genetic score that is the AMD risk increase per one additional risk allele with average effect size.

Additional association testing was performed by subgroups, separately for participants at higher age versus lower age (cutoff: age 75 years), for men and women, and by disease subtype (restricting the cases to GA or to NV/mixed GA + NV using the same controls). For the ocular specific diseases/traits, we additionally restricted the analysis to individuals from population-based studies to avoid possible confounding effects.

Identification of novel AMD-associated variants and loci {#Sec8}
--------------------------------------------------------

Given the substantial overlap of genetic disease/trait scores with AMD, we reasoned that shared pathways exist and that there might be even more AMD variants among those associated with other diseases/traits. Therefore, we computed the association with AMD for each variant used to compute any of the 60 genetic scores applying logistic regression adjusted for age, gender, DNA source, and the first two principle components. We controlled the FDR to be smaller than 1%. Variants located in one of the 34 known AMD-associated loci \[[@CR13]\] were considered to be known variants. To substantiate the independence of the selected variants, we additionally conducted the analyses adjusting for all of the 52 independent AMD-associated variants.

Pathway enrichment analysis based on novel and known AMD risk variants {#Sec9}
----------------------------------------------------------------------

To derive information on potential genes influenced by the observed association signal, we extracted all genes of a region around the respective variant. Here, we used the same locus definition as previously reported \[[@CR13]\] (most distant variant with R^2^ \> 0.5 in a region ± 100 Kbp). In addition, we added the genes from 34 known AMD loci \[[@CR13]\]. The resulting gene list was subjected to pathway enrichment analysis using INRICH \[[@CR87]\]. We queried significantly enriched KEGG, GO, and Reactome pathways and required at least four genes of the gene list to be present in the respective pathway. The FDR was controlled at 1%.

Annotation of novel associated and linked variants {#Sec10}
--------------------------------------------------

We extracted the position of novel associated variants as well as their correlated variants (R^2^ \> 0.5) and used the Variant Effect Predictor on [www.ensembl.org](http://www.ensembl.org/) to find variants in the coding region of a gene \[[@CR88]\].

Results {#Sec11}
=======

Selection of variants and computation of genetic scores {#Sec12}
-------------------------------------------------------

We extracted 1876 independent genome-wide significant variants for 60 diseases/traits from previously published sources (Additional file [1](#MOESM1){ref-type="media"}: Figure S1 and Additional file [2](#MOESM2){ref-type="media"}: Table S1). For each disease/trait, we computed a weighted genetic score in our 16,144 cases with late-stage AMD (NV AMD, GA, or both NV/GA AMD) and 17,832 controls without signs of early-stage or late-stage AMD. Additionally, we computed a genetic score for AMD based on the 52 identified AMD variants \[[@CR13]\].

Pairwise correlation of genetic scores {#Sec13}
--------------------------------------

To understand the dependencies between the genetic scores, pair-wise correlation coefficients of the scores were investigated (Fig. [1](#Fig1){ref-type="fig"}). We observed plausible correlations between genetic scores particularly of traits related to autoimmunity (inflammatory bowel disease, Crohn's disease and ulcerative colitis, rheumatoid arthritis (RA), PSO; Spearman correlation coefficient r in the range of 0.01--0.85), cardiovascular disease risk, and lipid levels in blood (blood pressure, coronary artery disease, hypertension, high density lipoprotein (HDL), low density lipoprotein (LDL), total cholesterol and total glycerol; r in the range of -0.36--0.98). Interestingly, the score for the glaucoma-related trait "optic disc/disc area" (ODDA) was not correlated to the genetic score of primary open angle glaucoma (POAG, r = 0.00), indicating that both phenotypes share no known genetic overlap. In summary, these correlations are in line with known relationships of the respective diseases and traits \[[@CR24], [@CR40]\] and with previously published correlations between genetic loci of diseases/traits \[[@CR89]\]. On average, the 60 genetic scores explain 4.81% of the variance of each disease/trait.Fig. 1Pairwise correlation between selected genetic scores. The *color key* represents the strength of the correlation between pairs of genetic scores, estimated as the correlation coefficient. The numbers on the bottom half of the graph indicate the correlation coefficient. The numbers in the top half indicate the statistical significance of the observed correlation coefficient (\*Q-value \< 0.01, \*\*Q-value \< 0.001, \*\*\*Q-value \< 0.0001). The abbreviations used for each trait are listed in Additional file [2](#MOESM2){ref-type="media"}: Table S1

Association of genetic scores with AMD {#Sec14}
--------------------------------------

Next, we investigated the association of the 60 calculated genetic scores with AMD using logistic regression models, adjusted for age, gender, DNA source, and the first two principle components. We found a statistically significant association for the genetic scores for 16 diseases/traits with AMD when controlling the FDR to be at 1% (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}). Three genetic scores related to autoimmunity (PSO, RA, and systemic lupus erythematosus \[SLE\]) were associated with increased risk for AMD, suggesting that participants at increased risk for autoimmune-related diseases are at higher risk for AMD. The remaining seven autoimmune-related genetic scores were consistent in trend (i.e. higher genetic scores are associated with higher AMD risk), although they failed to reach statistical significance. Similarly, we found increased AMD risk for higher genetic scores for elevated C-reactive protein (CRP).Fig. 2Association of 60 genetic scores with AMD. Logistic regression models, adjusted for age, gender, the first two principle components computed from the genotypes as well as DNA source were fitted for 60 genetic scores of selected complex diseases and traits. LOR (*squares*) and 95% confidence intervals (*horizontal lines*) obtained for each genetic score are plotted. \*Q-value \< 0.01, \*\*Q-value \< 0.001, \*\*\*Q-value \< 0.0001 Fig. 3Relationship between complex diseases/traits and AMD based on significant genetic score associations. *Nodes* represent diseases or traits and are colored according to uniform color scheme (see also Fig. [2](#Fig2){ref-type="fig"} and Additional file [2](#MOESM2){ref-type="media"}: Table S1). The size of each node represents the effect size of the association with AMD. Diseases and traits within distinct disease categories (see also Fig. [2](#Fig2){ref-type="fig"}) are connected with *lines* colored according to the respective disease category. *Lines* connecting AMD and diseases/traits indicate the direction of the association with *red lines* indicating an adverse association and *blue lines* representing protective associations. *Gray lines* depict interactions according to literature which could not be confirmed by genetic scores or were not investigated within this study. The numbers in *brackets* indicate the references which either support or dispute the respective interaction. The colors of the numbers indicate whether the cited literature reported an adverse (*red*) or a protective (*blue*) interaction. In case a finding is novel, no literature reference is presented on a connection between nodes

Interestingly, our findings revealed that participants with higher scores for cardiovascular diseases such as hypertension (HTN) or coronary artery disease (CAD) are at decreased risk for AMD. In line with this, participants with more alleles that increase blood pressure have a reduced risk of developing AMD. Furthermore, several scores related to adverse lipid levels in blood are associated with decreased AMD risk: participants with lower HDL genetic scores and higher LDL and total glycerol genetic scores were found to have decreased risk of AMD (Fig. [2](#Fig2){ref-type="fig"}). Participants with more alleles for higher bone-mineral density levels in the femoral neck (BMDFN) have decreased risk for AMD. Although we did not find a consistent trend for the association of genetic scores of various types of cancer and AMD, we found that participants at higher genetic risk for cutaneous malignant melanoma (CMM) have an increased risk for AMD. This association can, however, not be attributed to a single variant in the CMM score, since none of the 20 variants used to calculate the score was individually found to be significantly associated with AMD.

Next, we investigated the association of genetic scores of eye-related diseases/traits with AMD risk (Fig. [2](#Fig2){ref-type="fig"}, Additional file [1](#MOESM1){ref-type="media"}: Figure S2). We found a highly significant association of the myopia genetic score with AMD revealing a strong protective effect. Similarly, AMD patients have fewer risk alleles generally implicated in POAG and related traits of the optic disc area (optic disc cup area \[ODCA\] and vertical cup to disc ratio \[VCDR\]). Since the controls of our study were largely recruited in ophthalmologic clinics, it is possible that the association of glaucoma genetic scores can be explained by an enrichment of individuals with glaucoma in our controls. We therefore investigated the association of the glaucoma and related genetic scores restricted to study participants from population-based (cross-sectional) studies. This analysis included 6412 individuals and revealed a consistent protective association of POAG and ODCA with AMD (Additional file [1](#MOESM1){ref-type="media"}: Figure S2). Of note, the association of VCDR and myopia (MYP) was markedly weaker in individuals recruited in population-based studies (Additional file [1](#MOESM1){ref-type="media"}: Figure S2).

Association of candidate variants with AMD {#Sec15}
------------------------------------------

Given the association of genetic scores for several diseases with AMD risk indicating an overlap of various disease etiologies with AMD, we were interested to search for novel AMD-associated variants among those identified. Therefore, we analyzed the 1824 variants used for the calculation of the 60 scores for potential association with AMD risk. To account for multiple testing, we again controlled the FDR at 1%. Consequently, 31 novel variants were found to be associated with AMD risk (Q-value \< 0.01, p values 1.07 × 10^--7^ to 3.0 × 10^--4^; Additional file [3](#MOESM3){ref-type="media"}: Table S2). Moreover, this association was conditioned for 52 AMD-associated risk variants to exclude the significant association signals which may be due to linkage to any of the 52 known AMD associated variants. Following this adjustment, 28 variants remained significantly associated with AMD risk (Q-value \< 0.01, Table [1](#Tab1){ref-type="table"}).Table 1Single variant analysis of variants significantly associated with AMD riskOriginal studyAssociation with AMDFrequency inVariantChromo somePosition \[hg19\]PhenotypeLocus nameLocus boundary in 1 M bp \[hg19\]Effect allele^a^Effect size^a^Odds ratio95% CI^b^*p* value raw*p* value adj^c^Q-value rawQ-value adj^c^ControlsCasesImputation qualityrs75232731207977083SCZ*CD46/CR1L*207.8--208.1A1.063 (OR)1.0781.042-1.1161.37E-052.51E-050.00095.91E-050.6670.6810.972rs15500942233385396MYP*PRSS56*233.3--233.5G1.087 (HR)1.0671.030-1.1060.00030.00190.00930.00210.2900.3040.867rs98446663135974216HGT*STAG1*135.5--136.9G1.024 (SL)1.0791.039-1.1206.70E-050.00020.00290.00030.7530.7680.999rs74323753136288405SCZ*STAG1*135.5--136.9G1.073 (OR)0.9420.911-0.9730.00030.00040.00950.00050.6050.5930.999rs130911823141133960MYP*ZBTB38*141--141.3G1.064 (OR)0.9290.898-0.9601.65E-055.65E-060.00102.26E-050.6680.6510.996rs37749594103511114UC*NFKB1*103.3--103.6A1.119 (OR)0.9280.898-0.9591.11E-054.44E-070.00077.71E-060.3570.3410.964rs22770275156932376LGF*ADAM19*156.8--157.1A1.462 (SL)1.0961.059-1.1331.31E-072.75E-061.50E-051.28E-050.6510.6671.000rs2814982634546560TC*C6ORF106*34.4--34.9C1.045 (SL)1.1181.061-1.1782.67E-054.82E-050.00140.00010.8890.8980.980rs2207139650845490BMI*TFAP2B*50.7--51G1.046 (SL)0.9210.883-0.9610.00010.00040.00580.00060.1790.1650.997rs11776767810683929TG*PINX1*10.5--10.8C1.022 (OR)0.9360.905-0.9678.83E-050.00890.00370.00890.3800.3700.999rs3217992922003223CAD*CDKN2B*21.9--22.2T1.160 (OR)0.9140.884-0.9451.07E-071.18E-051.35E-053.67E-050.3940.3751.000rs7865618922031005ODCA; VCDR*CDKN2B*21.9--22.2A1.023 (SL)0.9370.907-0.9689.23E-056.12E-050.00370.00010.5930.5791.000rs7866783922056359POAG*CDKN2B*21.9--22.2G1.451 (OR)0.9360.906-0.9676.67E-052.53E-050.00295.91E-050.5940.5790.995rs1119154810104846178BP*NT5C2*104.4--105.2T2.989 (SL)0.9020.853-0.9540.00030.00120.00920.00140.9140.9061.000rs1119156010104869038BMI*NT5C2*104.4--105.2C1.031 (SL)1.1101.049-1.1730.00030.00120.00870.00140.0860.0940.996rs6345521175282052HGT*SERPINH1*75.2--75.4T1.040 (SL)1.1201.069-1.1732.08E-061.47E-050.00024.11E-050.1300.1440.999rs1183010312123823546HGT*SBNO1*123.3--124G1.036 (SL)1.0821.040-1.1259.13E-050.00280.00370.00290.2050.2161.000rs49019771460789176VCDR*SIX6*60.7--61.3T1.011 (SL)0.9270.895-0.9591.56E-058.40E-060.00102.94E-050.3190.3060.996rs20932101460957279HGT*SIX6*60.7--61.3C1.033 (SL)0.9200.890-0.9505.00E-071.37E-064.34E-057.71E-060.4170.4010.997rs339123451460976537POAG*SIX6*60.7--61.3C1.320 (OR)0.9190.889-0.9493.51E-071.19E-063.21E-057.71E-060.4130.3971.000rs104837271461072875ODCA*SIX6*60.7--61.3T1.026 (SL)0.9150.886-0.9461.11E-071.06E-061.35E-057.71E-060.4140.3960.999rs15553991467984370PD*PLEKHH1*67.9--68.1T1.115 (OR)0.9290.899-0.9596.27E-060.00020.00040.00030.5170.5020.997rs116270321493104072BRC*RIN3*93--93.2T1.060 (OR)1.0701.032-1.1090.00020.00140.00860.00150.7280.7390.931rs13789421575077367BP*CSK*74.9--75.3C1.846 (SL)0.9180.887-0.9508.52E-071.38E-067.06E-057.71E-060.3450.3281.000rs22904001738066240T1D*GSDMB*37.8--38.2C1.080 (OR)1.0681.034-1.1035.47E-057.29E-050.00260.00010.4940.5081.000rs93032801738074031ALG*GSDMB*37.8--38.2C1.070 (SL)0.9410.911-0.9710.00020.00010.00680.00020.5100.4970.984rs3860001954792761HDL*LILRA3*54.7--54.9C1.049 (SL)1.0961.053-1.1416.24E-060.00060.00040.00080.1990.2110.782rs15470142229100711VCDR*CHEK*28.5--29.2C1.013 (SL)0.9360.904-0.9690.00026.78E-050.00680.00010.7080.6950.999^a^Risk-/trait-increasing allele and effect size in the original study (*OR* odds ratio, *SL* slope, *HR* hazard ratio) (see Additional file [2](#MOESM2){ref-type="media"}: Table S1 for further details)^b^95% CI = 95% confidence interval of AMD OR estimate^c^Association of variant adjusted for 52 AMD-associated risk variants

Next, we extracted the variants correlated to the respective top variant at each locus (R^2^ \> 0.5) and annotated these using the Variant Effect Predictor \[[@CR88]\]. In total, we identified 12 non-synonymous and 13 synonymous variants (Table [2](#Tab2){ref-type="table"}).Table 2Coding variants in novel AMD-associated lociVariantTop variantChromosomePosition \[hg19\]r^2^ to top variantFrequency of variantAffected geneConsequencePhenotypeLocus nameLocus boundary in 1 M bp \[hg19\]rs6683902rs752327312078815570.5450.563CR1Lp.I455VSCZ*CD46/CR1L*207.8--208.1rs2796257rs752327312078908660.5490.434CR1Lp.L491PSCZ*CD46/CR1L*207.8--208.1rs1550094rs155009422333853961.0000.310PRSS56p.A30TMYP*PRSS56*233.3--233.5rs9860801rs984466631360880380.5470.302STAG1p.F403FHGT*STAG1*135.5--136.9rs1052620rs984466631365745210.9560.189SLC35G2p.L407LHGT*STAG1*135.5--136.9rs1422795rs227702751569363640.9960.357ADAM19p.S17GLGF*ADAM19*156.8--157.1rs943037rs11191548101048359190.9880.088CNNM2p.A770ABP*NT5C2*104.4--105.2rs584961rs63455211752776280.6250.888SERPINH1p.L78LHGT*SERPINH1*75.2--75.4rs12811109rs11830103121234710940.8380.216PITPNM2p.H1205HHGT*SBNO1*123.3--124rs1051431rs11830103121236458030.8780.768MPHOSPH9p.Y935HHGT*SBNO1*123.3--124rs6488868rs11830103121237999740.7560.722SBNO1p.G1022GHGT*SBNO1*123.3--124rs1060105rs11830103121238062190.9880.223SBNO1p.S729NHGT*SBNO1*123.3--124rs61388686rs11830103121238108730.5910.664SBNO1p.I567IHGT*SBNO1*123.3--124rs12322888rs11830103121238255591.0000.225SBNO1p.K209KHGT*SBNO1*123.3--124rs1254319rs1048372714609037570.6130.301C14orf39p.L524FODCA*SIX6*60.7--61.3rs33912345rs1048372714609765370.9780.597SIX6p.H141NODCA*SIX6*60.7--61.3rs117068593rs1162703214931182290.5650.187RIN3p.R279CBRC*RIN3*60.7--61.3rs2470890rs137894215750474260.8430.596CYP1A2p.N516NBP*CSK*74.9--75.3rs4886615rs137894215751316610.5530.691ULK3p.A302ABP*CSK*74.9--75.3rs907092rs229040017379222590.7610.473IKZF3p.S399ST1D*GSDMB*37.8--38.2rs11557466rs229040017380246260.7920.472ZPBP2p.L7LT1D*GSDMB*37.8--38.2rs11557467rs229040017380286340.9240.508ZPBP2p.S55IT1D*GSDMB*37.8--38.2rs10852935rs229040017380316740.7920.472ZPBP2p.C174CT1D*GSDMB*37.8--38.2rs2305480rs229040017380621960.8150.466GSDMBp.P302ST1D*GSDMB*37.8--38.2rs2305479rs229040017380622170.9480.502GSDMBp.G295RT1D*GSDMB*37.8--38.2

Finally, we defined AMD associated loci around the top variants with the boundaries comprising the most distant variant with R^2^ \> 0.5 and added a margin of 100 Kbp to both boundaries. In total, the 28 novel variants defined 20 loci associated with late-stage AMD (Table [1](#Tab1){ref-type="table"}) and thus implicated potential novel genes involved in disease risk. We extracted the genes located in the 20 novel and 34 known loci \[[@CR7]\] and used INRICH to perform pathway enrichment analysis. This approach strengthens the notion that complement activation is the main pathway involved in AMD risk (Reactome NCBI *Regulation of complement cascade*: Q-value = 0.0006, GO *Regulation of complement activation*: Q-value = 0.002). No other pathway reached the significance threshold (Q-value \< 0.01, Additional file [4](#MOESM4){ref-type="media"}: Table S3).

Discussion {#Sec16}
==========

Here, we show an association of genetic scores of 16 different diseases/traits with late-stage AMD. Most notably, we found genetic scores of autoimmune diseases (PSO, RA, and SLE), cardiovascular health (CAD, general blood pressure \[GBP\], HTN) and lipid levels (HDL, LDL, and triglyceride \[TG\]) to be associated with AMD. Remarkably, the genetic score for BMDFN as well as the genetic score for CMM were also associated with AMD. We also found that several genetic scores related to other ocular diseases (POAG, VCDR, MYP, and ODCA) are associated with AMD risk. Under the assumption that a genetic score summarizes the known genetic factors for a disease/trait, we conclude that these 16 diseases/traits share etiological properties with AMD.

Our findings point to two major areas of interest. First, we demonstrate that genetic scores related to autoimmunity are associated with AMD with adverse effects, in agreement with the observation that the presence of either PSO, RA, or SLE resulted in a higher risk for AMD \[[@CR90]--[@CR92]\]. Overall, all of the autoimmunity-related scores were higher in AMD patients than in controls. This strengthens the notion that AMD greatly overlaps with or possibly is an autoimmune-related disease. It remains to be seen whether these patients at risk for AMD might profit from anti-inflammatory or immuno-suppressive medication \[[@CR93]--[@CR95]\].

Second, individuals with increased genetic risk for cardiovascular disease and related traits have a lower risk for AMD, which could potentially be explained by a survival bias since our cases are on average two years older than our controls. Nevertheless, by adjusting for gender and age, we should be able to account for the findings. Still, we find a strong association of cardiovascular disease traits with AMD. Such a protective effect of cardiovascular-related genetic scores for AMD is in line with previous results \[[@CR96], [@CR97]\], despite disparate reports by other groups \[[@CR98]--[@CR101]\]. The latter discordance may be explained by factors other than genetic influences on cardiovascular disease risk and such factors may be elevated in late-stage AMD patients. For example, it has long been recognized that HDL plays a crucial role in preventing cardiovascular disease and is believed to be neuroprotective while reducing the risk for other neuropathies, e.g. Alzheimer's disease \[[@CR102]\] due to anti-inflammatory and anti-oxidant properties \[[@CR103]\]. According to our findings, AMD patients should have higher HDL, lower LDL, and lower total glycerol levels in their serum compared with controls, well in agreement with published data \[[@CR104]--[@CR106]\]. On another note, high levels of HDL and low total glycerol have been correlated with increased complement activation \[[@CR104], [@CR107]\]. This could explain the observed association where variants causing high HDL levels are also associated with increased CRP levels in serum \[[@CR104]\], additionally increasing complement activation levels \[[@CR55]\]. This is in line with the observation that elevated CRP levels are a risk factor for AMD \[[@CR108], [@CR109]\]. The risk for AMD may be increased by the same factors due to increased complement activation.

The association of genetic scores of ocular traits with AMD requires a more in-depth consideration. While the genetic scores for central cornea thickness (CCT) and ODDA are not associated with AMD, the remaining genetic scores associated with glaucoma (POAG, ODCA, and VCDR) as well as the genetic score for myopia were protective for AMD. Under the assumption that our controls are enriched for glaucoma and myopia cases, a conceivable expectation for a hospital-based recruitment of controls, the identified association could be explained but would render this finding an artefact. Controls are often enrolled as patients visiting the clinic for reasons other than AMD and may thus be enriched for other prevalent ocular diseases. Furthermore, AMD cases with myopia may be less frequently recruited since grading of AMD can be difficult in the presence of high myopia. Consequently, there may be fewer myopia patients in the patient cohort. On the other hand, population-based studies, i.e. studies randomly recruiting patients and controls in a community setting, should not be compromised by an enrichment of any ocular disease unless they share a similar genetic or non-genetic risk. Testing our dataset for this possibility showed that the association of the genetic scores in the population-based studies remained unchanged when comparing to the entire data including case-control studies with the exception of the VCDR and MYP genetic scores. From this, we conclude that AMD patients indeed have a genetically reduced risk to develop open angle glaucoma, although a smaller study found an adverse relationship between AMD and POAG using summary statistics \[[@CR110]\]. Conversely, we found no association of the myopia genetic score with AMD in our dataset in the population-based studies, in line with previous reports \[[@CR111]--[@CR114]\].

A surprising finding was the association of bone-mineral density genetic scores with AMD. Both scores of bone-mineral density (in the femoral neck and in the lumbar spine) are nominally significant, suggesting a protective effect for AMD in individuals having a higher bone-mineral density. Interestingly, vitamin D deficiency was linked to incident AMD in the CARED study \[[@CR115]\] and bone-mineral density can be increased with vitamin D supplementation \[[@CR116]\]. Of note, neither the genetic score of serum calcium concentration nor vitamin D concentration was found to be significantly associated with AMD. Nevertheless, these findings could point to future studies that explore vitamin D and calcium supplementation to prevent AMD.

The significant association of CMM with AMD is not due to a single variant associated with both diseases, as none of the 20 variants used for the calculation of the genetic score by itself was significantly associated with AMD. The effect seems to result from an accumulation of all 20 variant effect sizes (mean LOR = 0.018). A possible explanation may be that pigmentation plays a role in both diseases. CMM is a cancer type affecting the skin and associations with different characteristics of pigmentation are described \[[@CR117]\]. In general, people with lighter skin have a higher melanoma risk \[[@CR118]\]. This is in accordance with observations that Caucasians are more likely to be affected by AMD compared with black individuals \[[@CR119]\].

Our candidate variant approach was restricted to variants significantly associated with other diseases/traits and revealed 20 novel AMD-associated loci with 28 AMD associated variants. These variants have been implicated in other diseases/traits with genome-wide significance and therefore represent compelling novel findings, although these novel loci do not harbor genes that provide insights into so far unknown AMD-associated pathways. However, the newly identified loci strengthen the notion that AMD disease is extensively related to pathologic complement activation with the discovery that variants in the *CD46/CR1L* locus are significantly associated with AMD. In subsequent studies, in-depth bioinformatics and molecular evaluation of these risk signals need to be performed, particularly in the light of pathways and mechanisms associated with both AMD and the relevant disease/trait.

The results of this study are in accordance with the antagonistic pleiotropy theory of aging \[[@CR120]\], which states that many pleiotropic genetic factors are beneficial at younger ages (by either increasing fecundity or survival) while possibly unfavorable later in life by influencing senescence and thus age-related disease processes \[[@CR121]\]. We speculate that this could also be true for pleiotropic variants associated with AMD. For instance, increased immune activity could be advantageous at younger ages by reducing the risk for infections, but could ultimately lead to self-tissue damage causing autoimmune disease and late-stage AMD. Similarly, increased HDL and lower LDL levels result in improved cardiovascular health, which is an important factor to survive to old age. However, these same processes can cause late-stage AMD and might persist in populations due to a lack of negative selection in the elderly. As a consequence, our findings challenge the prospects of gene/genome manipulations to target a selected complex disease or trait, since seemingly beneficial genetic manipulations targeting a specific disease might in fact result in a seemingly unrelated disease at old age or accelerate aging in consequence.

Conclusions {#Sec17}
===========

Our findings suggest a substantial overlap of the genetics of autoimmune diseases, cardiovascular traits, lipid metabolism, cancer and metabolic traits as well as other eye-related diseases and traits with AMD. Investigating the association of variants associated with other diseases proves worthwhile to identify novel AMD risk variants and further implicates the complement system as the major pathway involved in AMD pathology.
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